Navigation Links
AEterna Zentaris Announces Appointment of New Board Member
Date:12/9/2009

.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are required by a governmental authority or applicable law.

SOURCE AETERNA ZENTARIS INC.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
2. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
3. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
4. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
5. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
6. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
7. AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency
8. AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer
9. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
10. AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
11. AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Cynvenio, a cancer ... through the genomic analysis of tumor cells in the ... a web-based cancer decision support application powered by CollabRx, ... Cynvenio’s ClearID™ genomic test, Therapy Finder will provide breast ...
(Date:1/15/2014)... , Jan. 15, 2014 ­ RedBrick Health ... behavior change technology, today announces that EmblemHealth , ... and wellness company, is now providing the RedBrick Compass ... coaching program, to all of its members. EmblemHealth is ...
(Date:1/15/2014)... A study has been launched to test whether technology ... help to tackle the problem of obesity.  This unique healthcare ... based in Stowmarket) and academics at University Campus Suffolk is ... which is inspired by equipment used to collect data about ...
(Date:1/15/2014)... Two champions of science, technology, engineering, and ... annual competition for middle and high school students designed ... study. The competition presents students with real-world problems experienced ... Mathematics, and Sciences is a program administered by ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5
... - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: ... been named the 2009 Life Sciences Company of the ... presented by LifeSciences British Columbia to recognize a local ... of British Columbia,s life sciences industry. This award recognizes ...
... Calif., April 9 Cell Biosciences, a provider of ... the closing of a $10 million Series C financing ... Existing investors Domain Associates, Latterell Venture Partners, Novo A/S, ... Group also participated in the financing."We are very happy ...
... April 9 Cepheid (Nasdaq: CPHD ) today ... first quarter ended March 31, 2009, on Thursday, April 23, ... a management presentation at 2 p.m. Pacific Time on Thursday, ... the live webcast, please visit Cepheid,s website at ...
Cached Biology Technology:OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia 2OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia 3Cell Biosciences Closes $10 Million Series C Financing 2Cepheid Schedules Fiscal 2009 First Quarter Financial Results Announcement and Webcast 2
(Date:4/17/2014)... IPCC meeting painted a stark warning on the possible ... a greenhouse effect 32 times that of carbon dioxide. ... humic substances act as fully regenerable electron acceptors which ... in wetlands instead of being released to the atmosphere. ... disrupted it may enter into a vicious cycle to ...
(Date:4/17/2014)... process whereby the genetic information of DNA is ... which have numerous different functions in living organisms. ... during gene expression, by relating the genetic information ... manufacturing proteins. , By examining the different ... an organism at a given time, researchers can ...
(Date:4/17/2014)... have uncovered a new way the immune system may ... efforts to use immune cells to treat illness. , ... the immunological equivalent of "neighborhood police" specialized squads ... organ, instead of an entire city, the body. , ... Louis have shown that the liver, skin and uterus ...
Breaking Biology News(10 mins):Methane climate change risk suggested by proof of redox cycling of humic substances 2Rapid and accurate mRNA detection in plant tissues 2Some immune cells defend only 1 organ 2
... dominant male and female to reduce their personal contribution to ... in Functional Ecology . , By removing the large ... cycle in this species a team from the University ... investment strategies of the dominant pair and the survival of ...
... Albert Einstein College of Medicine of Yeshiva ... as its twelfth Institutional Founding Member (IFM). A collaboration ... organizations, NYGC aims to transform medical research and clinical ... facilities in North America. "Einstein is pleased to ...
... directly lead to new ways of designing trials that would ... next few years and could change outcome for patients." ... 2013 will build on topics discussed in previous years and ... video here[ http://www.youtube.com/watch?v=X_anpC5WZPg ]: Breast cancer heterogeneity ...
Cached Biology News:Einstein joins the New York Genome Center as 12th institutional founding member 2IMPAKT -- Translational research breast cancer conference 2IMPAKT -- Translational research breast cancer conference 3
...
... the Adept CE 4100 high pressure dual piston ... wavelength detector for added flexibility. The ... and interface unit, CE 4901., The CE 4901 ... be used with Windows 98 and 2000, offers ...
Bis-Acrylamide (bis) is a monomer used as a crosslinker with acrylamide to form polyacrylamide electrophoretic gels. This 2% bis solution is supplied as 500 ml....
... G|2 Doublestain System is a high-sensitivity ... kit. The kit is intended for ... detection of two different antigens within ... with suitably diluted rabbit and mouse ...
Biology Products: